Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
Portfolio Pulse from Benzinga Newsdesk
Lisata Therapeutics has announced that the U.S. FDA has granted Orphan Drug Designation to LSTA1 for the treatment of malignant glioma. This designation provides certain benefits, including tax credits for clinical trials and market exclusivity upon regulatory approval.
August 08, 2023 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's Orphan Drug Designation for Lisata Therapeutics' LSTA1 could potentially lead to market exclusivity, which may positively impact the company's stock in the short term.
The Orphan Drug Designation by the FDA is a significant regulatory milestone that can lead to market exclusivity upon approval. This could potentially increase the demand for Lisata Therapeutics' stock as it indicates progress in the company's product pipeline and potential future revenue from LSTA1.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100